Ovarian Cancer GOG 9924

March 13, 2013

Location: The Hospital of Central Connecticut

A Phase I Pharmacokinetic Study Of Intraperitoneal CtepSupplied Agent Bortezomib (Ps-341, Nsc 681239, Ind# 58443) And Carboplatin (Nsc# 241240) In Patients With Persistent Or Recurrent Ovarian, Fallopian Tube, Or Primary Peritoneal Primary Cancer.